Mustang Bio (MBIO) vs Sunshine Biopharma (SBFM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Mustang Bio is the larger company by market cap ($3.2 million vs $1.9 million), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBIO | SBFM |
|---|---|---|
| Share price | $0.417 | $0.43 |
| Market cap | $3.16M | $1.85M |
| 1-day change | -7.37% | -38.57% |
| Forward P/E | — | 0.00 |
| EPS (TTM) | $-0.44 | $-9.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.81 | $24.30 |
| 52-week low | $0.41 | $0.356 |
| Distance from 52-week high | -76.96% | -98.23% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +12923.26% |
| Average volume | 29.38K | 5.25M |
| Shares outstanding | 6.73M | 4.31M |
| Employees | 4 | 50 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Healthcare · Biotechnology · 4 employees
About Sunshine Biopharma
SBFM stock →Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.
Healthcare · Drug Manufacturers - Specialty & Generic · 50 employees
MBIO vs SBFM FAQ
Which is bigger, Mustang Bio or Sunshine Biopharma?
Mustang Bio (MBIO) is larger, with a market capitalization of $3.16M compared with $1.85M for Sunshine Biopharma (SBFM).
Are Mustang Bio and Sunshine Biopharma in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Mustang Bio and Drug Manufacturers - Specialty & Generic for Sunshine Biopharma.